Revolution Medicines, Inc. (RVMD) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -1.63B USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 1.30B USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-1.63B | (m) | (m) | $1.30B | (m) | (m) |
| 2026-03-31 | $-1.39B | (m) | (m) | $1.13B | (m) | (m) |
| 2025-12-31 | $-1.18B | $0.00 | (m) | $987.33M | (m) | (m) |
| 2025-09-30 | $-1.04B | (m) | (m) | $880.49M | (m) | (m) |
| 2025-06-30 | $-897.50M | (m) | (m) | $769.15M | (m) | (m) |
| 2025-03-31 | $-789.42M | (m) | (m) | $679.95M | (m) | (m) |
| 2024-12-31 | $-689.52M | $0.00 | (m) | $592.23M | (m) | (m) |
| 2024-09-30 | $-653.20M | $742.00K | (m) | $552.61M | (m) | -88031.94% |
| 2024-06-30 | $-600.73M | $742.00K | (m) | $509.17M | (m) | -80961.32% |
| 2024-03-31 | $-552.89M | $4.57M | (m) | $472.22M | (m) | -12108.78% |
| 2023-12-31 | $-487.19M | $11.58M | (m) | $423.14M | (m) | -4207.12% |
| 2023-09-30 | $-368.91M | $26.17M | (m) | $340.79M | (m) | -1409.77% |
| 2023-06-30 | $-322.19M | $29.52M | (m) | $302.51M | (m) | -1091.30% |
| 2023-03-31 | $-275.49M | $34.82M | (m) | $265.53M | (m) | -791.27% |
| 2022-12-31 | $-258.28M | $35.38M | (m) | $253.07M | (m) | -730.01% |
| 2022-09-30 | $-249.49M | $29.51M | (m) | $240.63M | (m) | -845.43% |
| 2022-06-30 | $-226.12M | $27.25M | (m) | $217.65M | (m) | -829.63% |
| 2022-03-31 | $-208.56M | $26.84M | (m) | $202.58M | (m) | -777.14% |
| 2021-12-31 | $-188.01M | $29.39M | (m) | $186.95M | (m) | -639.70% |
| 2021-09-30 | $-169.18M | $28.68M | (m) | $170.27M | (m) | -589.85% |
| 2021-06-30 | $-143.56M | $40.24M | (m) | $158.67M | (m) | -356.76% |
| 2021-03-31 | $-127.01M | $41.57M | (m) | $145.65M | (m) | -305.55% |
| 2020-12-31 | $-110.70M | $42.98M | (m) | $132.25M | (m) | -257.54% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-54.12M | $50.04M | (m) | $91.75M | (m) | -108.15% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-40.33M | $20.16M | (m) | $51.08M | (m) | -200.00% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |